Biological rationale for the use of PPARγ agonists in glioblastoma

Frontiers in Oncology

Volumn 4 MAR, Issue , 2014, Pages

  Ellis, Hayley Patricia ^a   Kurian, Kathreena Mary ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Brain tumour; Glioblastoma multiforme; Glioma; PPAR gamma; Thiazolidinediones

Indexed keywords

15 DEOXY DELTA12, 14 PROSTAGLANDIN J2; BETA CATENIN; BETA TUBULIN; CATALASE; CD133 ANTIGEN; CIGLITAZONE; CYCLIN D1; CYCLIN DEPENDENT KINASE; GELATINASE A; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; NAVEGLITAZAR; NERVE CELL ADHESION MOLECULE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROTEIN BAX; PROTEIN BCL 2; RETINOIC ACID; ROSIGLITAZONE; STAT PROTEIN; TROGLITAZONE; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; BLADDER CANCER; BRAIN TUMOR; COLON CANCER; DNA POLYMORPHISM; G1 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; GLIOMA; HETEROZYGOTE; HUMAN; REVIEW;

EID: 84901048231     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00052     Document Type: Review

References (50)

1. Siersbæk MS, Loft A, Aagaard MM, Nielsen R, Schmidt SF, Petrovic N, et al. Genome-wide profiling of peroxisome proliferator-activated receptor γ in primary epididymal, inguinal, and brown adipocytes reveals depot-selective binding correlated with gene expression. Mol Cell Biol (2012) 32:3452-63. doi:10.1128/MCB.00526-12.
2. Nielsen R, Mandrup S. Genome-wide profiling of transcription factor binding and epigenetic marks in adipocytes by ChIP-seq. Methods Enzymol (2014) 537:261-79. doi:10.1016/B978-0-12-411619-1.00014-8.
3. Barish GD, Narkar VA, Evans RM. PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest (2006) 116:590-7. doi:10.1172/JCI27955.
4. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell (1995) 83:803-12. doi:10.1016/0092-8674(95)90193-0.
5. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARγ signaling and metabolism: the good, the bad and the future. Nat Med (2013) 9:557-66. doi:10.1038/nm.3159.
6. Lefterova MI, Steger DJ, Zhuo D, Qatanani M, Mullican SE, Tuteja G, et al. Cell-specific determinants of peroxisome proliferator-activated receptor gamma function in adipocytes and macrophages. Mol Cell Biol (2010) 30:2078-89. doi:10.1128/MCB.01651-09.
7. Sérandour AA, Avner S, Oger F, Bizot M, Percevault F, Lucchetti-Miganeh C, et al. Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res (2012) 40:8255-65. doi:10.1093/nar/gks595.
8. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. J Endocrinol (2001) 142:4195-202. doi:10.1210/en.142.10.4195.
9. Park K, Lee R, Kang S, Han S, Park K, Yang K, et al. Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway. Exp Cell Res (2004) 297:424-33. doi:10.1016/j.yexcr.2004.03.034.
10. Bugge A, Mandrup S. Molecular mechanisms and genome-wide aspects of PPAR subtype specific transactivation. PPAR Res (2010) 2010:169506. doi:10.1155/2010/169506.
11. Grommes C, Conway D, Alshekhlee A, Barnholtz-Sloan J. Inverse association of PPAR gamma agonists use and high grade glioma development. J Neurooncol (2010) 100:233-9. doi:10.1007/s11060-010-0185-x.
12. Zhou XP, Smith WM, Gimm O, Mueller E, Gao X, Sarraf P, et al. Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet (2000) 37:410-4. doi:10.1136/jmg.37.6.410.
13. Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 3:799-804. doi:10.1016/S1097-2765(01)80012-5.
14. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, et al. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun (2000) 270:400-5. doi:10.1006/bbrc.2000.2436.
15. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, et al. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A (2000) 97:10990-5. doi:10.1073/pnas.180329197.
16. Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev (2012) 30:368-402. doi:10.1080/10590501.2012.735519.
17. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell (1998) 1:465-70. doi:10.1016/S1097-2765(00)80047-7.
18. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science (2000) 289:1357-60. doi:10.1126/science.289.5483.1357.
19. Simula MP, Cannizzaro R, Canzonieri V, Pavan A, Maiero S, Toffoli G, et al. PPAR signaling pathway and cancer-related proteins are involved in celiac disease-associated tissue damage. Mol Med (2010) 16:199-209. doi:10.2119/molmed.2009.00173.
20. Tanaka T, Kohno H, Yoshitani S, Takashima S, Okumura A, Murakami A, et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res (2001) 61:2424-8.
21. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med (1998) 4:1058-61. doi:10.1038/2042.
22. Mansure JJ, Nassim R, Kassouf W. Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther (2009) 8:6-15. doi:10.4161/cbt.8.7.7853.
23. Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic changes in F-344 rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicol Pathol (2009) 37:741-53. doi:10.1177/0192623309343775.
24. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int J Cancer (2008) 123:2254-9. doi:10.1002/ijc.23765.
25. Zang C, Wächter M, Liu H, Posch MG, Fenner MH, Stadelmann C, et al. Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol (2003) 65:107-18. doi:10.1023/B:NEON.0000003728.80052.a8.
26. Chearwae W, Bright JJ. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer (2008) 99:2044-53. doi:10.1038/sj.bjc.6604786.
27. Liu D, Zang C, Liu H, Possinger K, Fan S, Elstner E. A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells. Acta Pharmacol Sin (2004) 25:1312-9.
28. Wan Z, Shi W, Shao B, Shi J, Shen A, Ma Y, et al. Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion. Mol Cell Biochem (2011) 349:1-10. doi:10.1007/s11010-010-0637-9.
29. Mo C, Chearwae W, Bright JJ. PPARgamma regulates LIF-induced growth and self-renewal of mouse ES cells through Tyk2-Stat3 pathway. Cell Signal (2010) 22:495-500. doi:10.1016/j.cellsig.2009.11.003.
30. Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, et al. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. J Neurooncol (2013) 15:198-207. doi:10.1093/neuonc/nos302.
31. Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M, et al. The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv (2012) 30:169-84. doi:10.1016/j.biotechadv.2011.08.001.
32. Villalva C, Martin-Lannerée S, Cortes U, Dkhissi F, Wager M, Le Corf A, et al. STAT3 is essential for the maintenance of neurosphere-initiating tumor cells in patients with glioblastomas: a potential for targeted therapy? Int J Cancer (2011) 128:826-38. doi:10.1002/ijc.25416.
33. Spagnolo A, Grant EN, Glick R, Lichtor T, Feinstein DL. Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes. Neurosci Lett (2007) 417:72-7. doi:10.1016/j.neulet.2007.02.036.
34. Ahmad I, Aykin-Burns N, Sim J, Walsh S, Higashikubo R, Buettner G, et al. Mitochondrial O-2(-center dot) and H2O2 mediate glucose deprivation-induced cytotoxicity and oxidative stress in human cancer cells. J Biol Chem (2005) 280:4254-63. doi:10.1074/jbc.M411662200.
35. Kanakasabai S, Pestereva E, Chearwae W, Gupta SK, Ansari S, Bright JJ. PPARγ agonists promote oligodendrocyte differentiation of neural stem cells by modulating stemness and differentiation genes. PLoS One (2012) 7:e50500. doi:10.1371/journal.pone.0050500.
36. Pestereva E, Kanakasabai S, Bright JJ. PPARγ agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells. Br J Cancer (2012) 106:1702-12. doi:10.1038/bjc.2012.161.
37. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer (2007) 96:1293-301. doi:10.1038/sj.bjc.6603696.
38. Hendrickx M, Van X, Leyns L. Anterior-posterior patterning of neural differentiated embryonic stem cells by canonical Wnts, Fgfs, Bmp4 and their respective antagonists. Dev Growth Differ (2009) 51:687-98. doi:10.1111/j.1440-169X.2009.01128.x.
39. Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem (2002) 81:1052-60. doi:10.1046/j.1471-4159.2002.00899.x.
40. Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M, et al. PPARgamma and RXRgamma ligands act synergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem (2009) 109:1779-90. doi:10.1111/j.1471-4159.2009.06111.x.
41. Grommes C, Landreth GE, Sastre M, Beck M, Feinstein DL, Jacobs AH, et al. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment. Mol Pharmacol (2006) 70:1524-33. doi:10.1124/mol.106.022194.
42. Rao J, Steck P, Mohanam S, Stetlerstevenson W, Liotta L, Sawaya R. Elevated levels of M(R) 92,000 type-IV collagenase in human brain-tumours. Cancer Res (1993) 53:2208-11.
43. Liu X, Wang L, Zhao S, Ji X, Luo Y, Ling F. Beta-catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Med Oncol (2011) 28:608-14. doi:10.1007/s12032-010-9476-5.
44. Khoo NKH, Hebbar S, Zhao W, Moore SA, Domann FE, Robbins ME. Differential activation of catalase expression and activity by PPAR agonists: implications for astrocyte protection in anti-glioma therapy. Redox Biol (2013) 1:70-9. doi:10.1016/j.redox.2012.12.006.
45. Ajjan RA, Grant PJ. The cardiovascular safety of rosiglitazone. Expert Opin Drug Saf (2008) 7:367-76. doi:10.1517/14740338.7.4.367.
46. Gillies PS, Dunn CJ. Pioglitazone. Drugs (2000) 60:333-43. doi:10.2165/00003495-200060020-00009.
47. Chen X, Yang L, Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies. Chin Med J (Engl) (2012) 125:4301-6.
48. Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, et al. Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab (2001) 86:3250-6. doi:10.1210/jc.86.7.3250.
49. Hulin B, Newton LS, Lewis DM, Genereux PE, Gibbs EM, Clark DA. Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone. J Med Chem (1996) 39:3897-907. doi:10.1021/jm960230h.
50. Scher JU, Pillinger MH. 15d-PGJ2: the anti-inflammatory prostaglandin? Clin Immunol (2005) 114:100-9. doi:10.1016/j.clim.2004.09.008.